Clinical data | |
---|---|
Trade names | Halcion, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a684004 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 44% (oral route), 53% (sublingual) |
Metabolism | Liver |
Onset of action | 15–30 minutes[4] |
Elimination half-life | 1.5–5.5 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.044.811 |
Chemical and physical data | |
Formula | C17H12Cl2N4 |
Molar mass | 343.21 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Triazolam, sold under the brand name Halcion among others, is a central nervous system (CNS) depressant tranquilizer of the triazolobenzodiazepine (TBZD) class, which are benzodiazepine (BZD) derivatives.[5] It possesses pharmacological properties similar to those of other benzodiazepines, but it is generally only used as a sedative to treat severe insomnia.[6][unreliable medical source?] In addition to the hypnotic properties, triazolam's amnesic, anxiolytic, sedative, anticonvulsant, and muscle relaxant properties are pronounced as well.[7]
Triazolam was initially patented in 1970 and went on sale in the United States in 1982.[8] In 2017, it was the 289th most commonly prescribed medication in the United States, with more than one million prescriptions.[9]